Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Riess

Showing results (71-80 of 136) with videos related to

Pageof 14
Sort By:
JTO Clinical and Research Reports|November 19, 2025
DLL3 Immunohistochemical Expression in Neuroendocrine-Transformed <i>EGFR</i>-Mutant Lung Cancer and Two Cases of Tarlatamab TherapyJacqueline V Aredo, Surbhi Singhal, Gerald J Berry, et al.
JTO Clinical and Research Reports|June 9, 2025
A Phase 1/1B Trial of Pembrolizumab and Trametinib in Advanced NSCLC Enriched for KRAS MutationsJonathan W Riess, Matthew S Lara, Guillaume Luxardi, et al.
JCO Precision Oncology|May 26, 2021
Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non-Small-Cell Lung CancerCaroline E McCoach, Aiming Yu, David R Gandara, et al.
Cancer|May 5, 2020
Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 casesPhilip C Mack, Kimberly C Banks, Carin R Espenschied, et al.
JTO Clinical and Research Reports|September 25, 2024
Immune Cell Dynamics in EGFR-Mutated NSCLC Treated With Afatinib and Pembrolizumab: Results From a Phase IB StudyJonathan W Riess, Matthew S Lara, Miguel Lopez de Rodas, et al.
Clinical Lung Cancer|June 18, 2021
Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878)Jonathan W Riess, Karen L Reckamp, Paul Frankel, et al.
Science Advances|July 21, 2023
Satellite reveals a steep decline in China's CO<sub>2</sub> emissions in early 2022Hui Li, Bo Zheng, Philippe Ciais, et al.
Lung Cancer (Amsterdam, Netherlands)|September 27, 2019
Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignanciesJessica A Hellyer, Matthew A Gubens, Kristen M Cunanan, et al.
Journal of Thoracic Imaging|December 9, 2017
Computed Tomography Features associated With the Eighth Edition TNM Stage Classification for Thymic Epithelial TumorsSukhmani K Padda, Donato Terrone, Lu Tian, et al.
The Oncologist|August 9, 2019
MET Genomic Alterations in Head and Neck Squamous Cell Carcinoma (HNSCC): Rapid Response to Crizotinib in a Patient with HNSCC with a Novel <i>MET</i> R1004G MutationLisa Pei Chu, Debra Franck, Christine A Parachoniak, et al.
Pageof 14

Showing results (71-80 of 136) with videos related to

Sort By:
Pageof 14
JTO Clinical and Research Reports|November 19, 2025
DLL3 Immunohistochemical Expression in Neuroendocrine-Transformed <i>EGFR</i>-Mutant Lung Cancer and Two Cases of Tarlatamab TherapyJacqueline V Aredo, Surbhi Singhal, Gerald J Berry, et al.
JTO Clinical and Research Reports|June 9, 2025
A Phase 1/1B Trial of Pembrolizumab and Trametinib in Advanced NSCLC Enriched for KRAS MutationsJonathan W Riess, Matthew S Lara, Guillaume Luxardi, et al.
JCO Precision Oncology|May 26, 2021
Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non-Small-Cell Lung CancerCaroline E McCoach, Aiming Yu, David R Gandara, et al.
Cancer|May 5, 2020
Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 casesPhilip C Mack, Kimberly C Banks, Carin R Espenschied, et al.
JTO Clinical and Research Reports|September 25, 2024
Immune Cell Dynamics in EGFR-Mutated NSCLC Treated With Afatinib and Pembrolizumab: Results From a Phase IB StudyJonathan W Riess, Matthew S Lara, Miguel Lopez de Rodas, et al.
Clinical Lung Cancer|June 18, 2021
Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878)Jonathan W Riess, Karen L Reckamp, Paul Frankel, et al.
Science Advances|July 21, 2023
Satellite reveals a steep decline in China's CO<sub>2</sub> emissions in early 2022Hui Li, Bo Zheng, Philippe Ciais, et al.
Lung Cancer (Amsterdam, Netherlands)|September 27, 2019
Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignanciesJessica A Hellyer, Matthew A Gubens, Kristen M Cunanan, et al.
Journal of Thoracic Imaging|December 9, 2017
Computed Tomography Features associated With the Eighth Edition TNM Stage Classification for Thymic Epithelial TumorsSukhmani K Padda, Donato Terrone, Lu Tian, et al.
The Oncologist|August 9, 2019
MET Genomic Alterations in Head and Neck Squamous Cell Carcinoma (HNSCC): Rapid Response to Crizotinib in a Patient with HNSCC with a Novel <i>MET</i> R1004G MutationLisa Pei Chu, Debra Franck, Christine A Parachoniak, et al.
Pageof 14